Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771247 | 0.88 | LRRK2 (0.43) | KDRLRRK2EGFRGRM4BPTF | |
| SCHEMBL16864476 | 0.81 | LRRK2 (0.40) | LRRK2HRH3EGFRGRM4 | |
| SCHEMBL3775329 | 0.81 | LRRK2 (0.61) | KDRLRRK2EGFRGRM4 | |
| SCHEMBL3766328 | 0.81 | IGF1R (0.46) | CDK1KDRLRRK2RETHRH3 | |
| SCHEMBL3763899 | 0.78 | GRM4 (0.51) | LRRK2EGFRGRM4 | |
| SCHEMBL3775370 | 0.78 | LRRK2 (0.63) | KDRLRRK2GRM4FLT1 | |
| SCHEMBL3774794 | 0.78 | GRM4 (0.50) | LRRK2EGFRGRM4 | |
| SCHEMBL13006149 | 0.78 | LRRK2 (0.42) | LRRK2EGFRGRM4 | |
| SCHEMBL3775083 | 0.77 | AXL (0.46) | LRRK2 | |
| SCHEMBL3764174 | 0.77 | CACNA2D1 (0.46) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | CDK1 1775/4885KDR 797/4885LRRK2 2309/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | CDK1 1780/4885KDR 726/4885LRRK2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.